Mat***luk

Chief Business Officer

学歴

Carnegie Mellon University - Tepper School of Business

Carnegie Mellon University - Tepper School of Business (2006 - 2008)

  • Degree: MBA
  • Field of Study: Entrepreneurship, Finance, Marketing, Strategy
  • Description: William G. McGowan Scholar, James R. Swartz Entrepreneurial Fellow, Tepper School of Business Merit Scholarship Recipient, Walter Rittman Endowed Scholar

University of Pittsburgh School of Medicine (Unknown - 2006)

  • Degree: PhD
  • Field of Study: Cell Biology, Biochemistry
  • Description: Dissertation: Protein Interaction Domains in Clathrin-Mediated Endocytosis.

University of Notre Dame (Unknown - Present)

  • Degree: BS
  • Field of Study: Biochemistry
  • Description:

スキル:

Business Development, Strategy, Biotechnology, Product Management

職務経験:

Chief Business Officer at AIRNA

  • Location:
  • Duration: 2025-01 to Present
  • Description:

Director, Board of Directors at OUROTECH, INC. (D.B.A. PEAR BIO)

  • Location: London, United Kingdom
  • Duration: 2024-07 to Present
  • Description:

Director, Board of Directors at Predictive Oncology

  • Location:
  • Duration: 2022-11 to Present
  • Description:

Advisory Board Member at PathAI

  • Location: Boston, Massachusetts, United States
  • Duration: 2020-03 to Present
  • Description:

EVP, Chief Business Officer & Boston Site Head at Gritstone bio

  • Location: Cambridge, MA
  • Duration: 2015-11 to 2025-01
  • Description: Executive Vice President and Chief Business Officer, 1/2015 – Present Head of Legal, 9/2022 – Present Boston Site Head (Previously Cambridge, MA), 7/2021 – Present Led several pivotal deals w/ Government and non-government partners • BARDA project and submission of Broad Agency Announcement application including Technical and Cost Volumes and negotiation of the contract to conduct a comparative 10,000 subject Phase 2b clinical trial evaluating a next-generation vaccine candidate for COVID-19 with funding valued up to $433M (Sep’23) • Collaboration, Option and License agreement with Gilead Sciences to research and develop an HIV cure (Jan’21), utilizing Gritstone technology for Gilead’s development and commercialization. Total deal value of $785M with $60M upfront • Research collaboration and license agreement with bluebird bio (now 2seventy bio) whereby Gritstone provides tumor-specific targets and TCRs for cell therapy (Aug’18). Total deal value of $1.2B with $20M upfront cash and $20M in equity ($10M in Series C and $10M in IPO) • Grant agreements with Bill & Melinda Gates Foundation funding for an optimal immunogen for HPV eradication ($3.2M) and for a next-generation SARS-CoV-2 vaccine ($575K) • Funding agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a second-generation samRNA SARS-CoV-2 vaccine in South Africa. Funding up to $25.6M for a multi-arm Phase 1 study, preclinical studies, and scale-up, and formulation development
AI履歴書分析

候補者インテリジェンスレポート

米国の採用ディレクターの視点からAI分析 — キャリアの継続性、成長軌道、および役職適合性を評価します。

キャリアの継続性とリスク評価

Employment GapLow

No gaps in employment are evident; the candidate has maintained continuous work in senior biotech leadership and advisory roles since 2015.

Industry ConsistencyLow

Career across biotechnology, biopharma, and life sciences partnerships is highly consistent with educational background and skill set.

Tenure StabilityLow

A long tenure at Gritstone (2015–2025) demonstrates stability; subsequent transitions to AIRNA and ongoing governance roles are typical for senior biotech executives and not indicative of instability.

Education-Career MatchLow

CMU Tepper School of Business credentials align with C-suite BD/strategy roles in biotech, supporting a strong education-career fit.

キャリア成長カーブ

EVP, Chief Business Officer & Boston Site Head Entry
Gritstone bio
2015-11 to 2025-01
Boston Site Head ↑ 昇進
Gritstone bio
2021-07 to 2025-01
Head of Legal ↑ 昇進
Gritstone bio
2022-09 to 2025-01
Advisory Board Member Lateral
PathAI
2020-03 to Present
Director, Board of Directors Lateral
Predictive Oncology
2022-11 to Present
Director, Board of Directors Lateral
OUROTECH (D.B.A. PEAR BIO)
2024-07 to Present
Chief Business Officer Entry
AIRNA
2025-01 to Present
評価:Matthew demonstrates a clear upward trajectory with deep biopharma business development, strategic partnerships, and board governance experience. The progression to AIRNA as CBO, along with multiple board/advisory roles, positions him for CEO or Chief Strategy/Commercial leadership roles at a growth-stage or mature biotech organization.

最適な役職(トップ5)

1

Chief Executive Officer (CEO)97% 適合

Proven P&L leadership, extensive deal-making at scale (e.g., HIV cure collaboration, COVID-19 vaccines), and multi-board governance experience, all of which align with steering a biotech company toward growth and commercialization milestones.

2

Chief Commercial Officer (CCO) / Chief Business Officer (CBO)92% 適合

Direct alignment with a decade of business development and strategic partnerships, including major industry deals and government collaborations; strong network across pharma and biotech partners.

3

Chief Strategy Officer (CSO) / Head of Corporate Development90% 適合

Expertise in formulating growth strategies and negotiating high-value collaborations; well-suited to align product portfolios with market opportunities and corporate strategy.

4

Non-Executive Director (Board Director) – Life Sciences85% 適合

Extensive board governance experience across multiple biotech entities; brings risk oversight, strategic judgment, and stakeholder management to boards.

5

Senior Vice President, Corporate Development82% 適合

Deep experience in licensing, collaborations, and strategic partnerships; ideal for driving growth initiatives within a larger biopharma/biotech organization.

AI Recruiterを体験する

無料で始めましょう。ライバルに先を越されないでください。

AI駆動の採用ソリューションを活用して、採用プロセスを自動化し、時間コストの80%を削減している10,000社以上の企業に加わりましょう。

33%オフ、残り48時間のみ!
AIを無料で試す

24時間365日自動運用

AIを活用した候補者スクリーニング

地理的・時差の制限なく採用活動

パーソナライズされたインテリジェントコミュニケーション

候補者エンゲージメントの自動評価

あなたの採用スタイルをインテリジェントに模倣・再現

4ヶ月間の返金保証

LinkedInアカウントのセキュリティを確保